Early growth response factor-1 (Egr-1) is a transcription factor that is rapidly activated after vascular injury and thus might contribute to vascular proliferation and inflammation. We hypothesized that Egr-1 might therefore be a therapeutic target against restenosis. Hypercholesterolemic rabbits were intraluminally administered synthetic DNA as a 'decoy' against Egr-1 immediately after carotid artery balloon injury. Efficient transfection was confirmed by the delivery of a fluorescence-labeled decoy. Gel mobility-shift assay showed increased Egr-1 activity after balloon injury and its prevention by Egr-1 decoy transfection in vivo. Egr-1 decoy transfection attenuated early inflammation and proliferation and later neointimal hyperplasia. In addition, Egr-1 decoy transfection reduced gene expression and protein production of Egr-1-dependent genes such as platelet-derived growth factor-B, transforming growth factor-b1, and monocyte chemoattractant protein-1. The Egr-1 pathway has an essential role in the pathogenesis of neointimal hyperplasia after balloon injury in hypercholesterolemic rabbits. This decoy strategy is a potential practical form of therapy for human restenosis.
Introduction
Atherosclerosis and restenosis following percutaneous coronary intervention are now recognized to result from proliferative-inflammatory responses to injury in the arterial wall. [1] [2] [3] Both balloon angioplasty and stent implantation are useful treatments for dilating atherothrombotic stenosis. 4, 5 The overall benefits of this intervention, however, are hampered by local arterial renarrowing (restenosis), which occurs in 30-50% of cases within 6 months. 4, 5 No pharmacologic strategies have demonstrated definite benefits to reduce the rate of restenosis. Although silorimus-eluting stents might suppress restenosis, 6 ,7 its benefits have not yet been completely established.
Experimentally, injury to the arterial wall by balloon or stents rapidly activates intracellular signals, such as mitogen-activated protein kinases, and various transcription factors, such as early growth response factor-1 (Egr-1). 8, 9 Egr-1 is an immediate-early gene product and a zinc-finger transcription factor that regulates a number of pathophysiologically relevant genes. 8, 10 Egr-1 is induced and activated after injury in vascular smooth muscle cells, endothelial cells, and leukocytes. A number of Egr-1-dependent genes are upregulated in human and experimental atherosclerotic lesions. 11, 12 Among a variety of transcription factors that are activated after arterial injury, Egr-1 might be a practical and ideal target for therapeutic intervention to prevent restenosis, because (1) Egr-1 is expressed at low or undetectable levels in the normal artery, and is rapidly upregulated by mechanical injury; (2) Egr-1 is activated by multiple stimuli that might contribute to the development of restenotic and atherosclerotic lesions; and (3) Egr-1 controls the expression of various genes whose products are related to the development of vascular lesion -factors that induce proliferation/migration (platelet-derived growth factor (PDGF), transforming growth factor-b1 (TGF-b1), matrix metalloproteinases), inflammation (monocyte chemoattractant protein (MCP)-1), and thrombosis (tissue factor). 8, 10 Khachigian et al 13 recently generated a DNAzyme that specifically cleaves Egr-1 mRNA and reported that adventitial delivery of the DNA enzyme with pluronic gel attenuated neointimal hyperplasia in balloon-injured rat carotid artery model, and that intraluminal delivery of the DNAzyme with the transport catheter inhibited in-stent neointimal hyperplasia of coronary arteries in pig model. 14 They did not, however, address the mechanism by which blockade of Egr-1 attenuated neointimal hyperplasia or causative factor(s) that might contribute to the inhibitory effects on neointimal hyperplasia under in vivo conditions. The delivery of anti-Egr-1 agents intraluminally might provide a reasonable starting point for clinical application of anti-Egr-1 against restenosis. Transfection of the DNAzyme into the arterial wall in vivo is difficult compared to transfection of DNA oligodeoxynucleotides (ODNs). 15 We and others previously demonstrated that cis-element 'decoy' ODNs of the transcription factor-binding site can be successfully transfected using an intraluminal approach and is effective in blocking the activity of several transcription factors. [15] [16] [17] Although there is no ideal experimental model available, the hypercholesterolemic rabbit model might be more relevant and appropriate for studying the usefulness of novel approaches against human restenosis.
Therefore, the primary aim of the present study was to test the hypothesis that blockade of Egr-1 activity reduces neointimal formation after balloon injury by inhibiting Egr-1-dependent proliferative-inflammatory changes in hypercholesterolemic rabbits. To achieve effective blockade of Egr-1 in vivo, we utilized transfection of synthetic double-stranded Egr-1 decoy ODNs. This decoy strategy involves the intracellular delivery of 'decoy' ODNs, which are then bound by Egr-1. Occupation of the Egr-1 DNA-binding site by the decoy ODN renders the protein incapable of binding to the promoter regions of the target genes.
Results
Egr-1 expression and activity in a balloon-injured artery Egr-1 mRNA was not detectable in normal noninjured artery. Egr-1 mRNA expression had biphasic changes; an early and rapid rise at 1 h, a spontaneous decline at 6 and 24 h, reinduction at 7 and 28 days after injury ( Figure 1a ). Immunohistochemical staining revealed increased Egr-1 protein levels in the medial cells at the early phase and in neointimal and medial cells at the later phase after balloon injury (Figure 1b) . To identify which cell types upregulate Egr-1, we performed double immunostaining (Figure 1c) . We found that immunoreactive Egr-1 located in monocytes/macrophages and smooth muscle cells in the media at the early phase of day 7, and in neointimal and medial vascular smooth muscle cells at later phase of day 28. Egr-1 was also present in the endoluminal endothelial cells on day 28.
Transfection of FITC-labeled Egr-1 decoy into the artery
Transfection of fluorescein-isothiocyanate (FITC)-ODNs resulted in widespread fluorescence in the medial layer of the injured arterial wall (Figure 2a) . The transfection efficacy (percent of FITC-stained nuclei per total nuclei) was 6.271.6%.
Gel mobility-shift assay revealed that the Egr-1-binding activity was markedly increased compared with that of normal noninjured artery (Figure 2b ). Complete competition of the increased Egr-1-binding activity by an excess Egr-1 decoy was observed. The increased Egr-1-binding activity was markedly diminished in the artery transfected with the Egr-1 decoy, but not in the artery transfected with the scrambled decoy ODN (Figure 2b ).
Inhibitory effects of the Egr-1 decoy transfer on neointimal hyperplasia
On day 7, we detected RAM-11-positive monocytes and Ki-67-positive proliferating cells mainly in the media (Figure 3a) . There was markedly less inflammation (RAM11-positive cells) and proliferation (Ki-67-positive cells) in Egr-1 decoy-transfected arteries than in untreated and scrambled decoy-transfected arteries (Figure 3b ).
On day 28, thickened neointima was formed in the balloon-injured artery of all three groups (Figure 4a ). Quantitative analysis demonstrated a significant reduction of the intima/media ratio in Egr-1 decoytransfected arteries compared with the other two groups (Figure 4c ). Endothelial cell linings, monitored by CD31 
Inhibitory effects of Egr-1 decoy transfer on expression of target genes
Egr-1 decoy transfection, but not scrambled decoy transfection, reduced the increased expression of PDGF-B, TGF-b1, and MCP-1 ( Figure 5a ). Egr-1 decoy transfection did not affect increased gene expression of interleukin (IL)-1b and TF. Immunohistochemical staining performed 7 days after balloon injury revealed increased immunoreactive PDGF-B, TGF-b1, and MCP-1 in cells in the neointima, and smooth muscle cells in the media (Figure 5b ). Increases in PDGF-B, TGF-b1, and MCP-1 immunostaining were not observed in Egr-1 decoy-transfected arteries.
Plasma lipoprotein levels
There was no significant difference in the time course of plasma levels of low-density lipoprotein cholesterol among the three groups. The low-density lipoprotein cholesterol levels before and 28 days after injury were 452747 and 471763 mg/dl in the untreated group, 491742 and 507735 mg/dl in the scrambled decoytransfected group, and 474732 and 538744 mg/dl in Egr-1 decoy-transfected group.
Discussion
Blockade of Egr-1 activation using the 'decoy' strategy attenuated early inflammation and proliferation and thus reduced later neointimal hyperplasia in balloon-injured arteries of hypercholesterolemic rabbits, suggesting that Egr-1 is an important target for restenosis. This study is the first to demonstrate the efficacy of Egr-1 decoy ODN transfection in vivo for restenosis therapy.
The most important finding in the present study is that blockade of Egr-1 activity by transfection of Egr-1 decoy ODN attenuated neointimal hyperplasia associated with the inhibition of inflammation (infiltration of RAM11-positive macrophages) and proliferation (appearance of proliferating cells). Also, Egr-1 decoy ODN transfection inhibited increased expression of Egr-1-dependent genes such as PDGF-B and TGF-b1 after balloon injury. Egr-1 decoy ODN transfection did not affect the expression of Egr-1-independent genes, such as IL-1b, suggesting specific inhibition of Egr-1-mediated gene transcription by Egr-1 decoy ODN transfection. Furthermore, there 
was increased immunoreactivity for PDGF-B, TGF-b1, and MCP-1 in balloon-injured arterial wall and increased inhibition by Egr-1 decoy ODN transfection. Neointimal hyperplasia is inhibited by blocking PDGF, 18, 19 TGFb1, 20, 21 or MCP-1. [22] [23] [24] Therefore, it is reasonable to consider that the mechanisms by which the Egr-1 decoy ODN transfection attenuates neointimal hyperplasia after balloon injury is by decreased expression and activity of these target genes.
We demonstrated direct in vivo evidence for specific activation (increased DNA-binding activity) of Egr-1 in the balloon-injured artery and effective suppression of Egr-1 activation by transfection of synthetic doublestranded Egr-1 decoy ODN. As we could not stain Egr-1 immunohistochemically in rabbit tissues with available antibodies, we performed immunohistochemical staining of Egr-1 in a rat model. Egr-1 expression after balloon injury is biphasic and Egr-1-expressing cells locate in monocytes/macrophages and smooth muscle cells in the media at early phases and in the neointimal and vascular smooth muscle cells in the media at late phases of balloon injury. Egr-1 is activated by multiple external stimuli (ie, mechanical injury, cytokines, growth factors) that might contribute to the pathogenesis of neointimal hyperplasia after injury; therefore, the present data suggest that Egr-1 also participates in the chronic process of neointimal hyperplasia. A recent report by McCaffrey et al, 11 who demonstrated persistent expression of Egr-1 in activated smooth muscle cells and endothelial cells in chronic stages of both experimental and human atherosclerosis, supports this notion. A caveat in the interpretation of the present data is the partial inhibition of neointimal hyperplasia. This might be due to the limited transfection efficiency of naked decoy ODN. Therefore, technologies that enhance transfection efficiency (ie, HVJ-liposome method, new catheters for decoy delivery) should be used for 'decoy' strategies in clinical gene therapy.
In conclusion, our present data suggest that Egr-1 has an important role in the pathogenesis of neointimal hyperplasia after balloon injury in hypercholesterolemic rabbits. The inhibitory effects of the Egr-1 decoy are explained by the inhibition of vascular inflammation and proliferation through decreased expression and activity of Egr-1-dependent genes. These results suggest that gene therapy using in vivo transfection of an Egr-1 decoy might be a new therapeutic option against restenosis. Recent studies reported that transfection of decoy ODN for other transcription factors (nuclear factor-kB, 25 activator protein-1 26 ) also reduced neointimal hyperplasia after injury, possibly through inhibitory effects different from those of Egr-1 decoy ODN transfection. A double decoy strategy that facilitates simultaneous suppression of two transcription factors, therefore, would be another novel approach for restenosis therapy.
Materials and methods

Egr-1 'decoy' oligonucleotides
A double-stranded phosphorothioate Egr-1 decoy ODN was synthesized. The Egr-1 decoy ODN sequence was: 5 0 -CCGAGAGCGGGGGCGAGCGTG-3 0 annealed to 5 0 -CACGCTCGCCCCGCTCTCGG-3 0 ; the sequence of the scrambled ODN, which included unrelated oligonucleotides, was 5 0 -GAGGCCGGCAGGTCGCGAGGG-3 0 annealed to 5 0 -CCCTCGCGACCTGCCGGCCTC-3 0 . Egr-1 ODN labeled with FITC at the 5 0 end of one strand was used for fluorescent microscopic analysis of ODN distribution after transfection.
Animal model of balloon injury
The present experiments were reviewed and approved by the Committee on Ethics on Animal Experiments, Kyushu University Faculty of Medicine, and according to the Guidelines of the American Physiologic Society. A part of this study was performed at the Kyushu University Station for Collaborative Research and the Morphology Core.
Male Japanese white rabbits weighing 2.7-3.2 kg were fed a high cholesterol diet containing 1% cholesterol and 3% peanut oil for 2 weeks. After anesthesia, the right common carotid artery was injured by three passages of an inflated 2F Fogarty catheter. 22 The sham operation involved simple ligation of the left external carotid artery without balloon injury. After the operation, all rabbits were fed the same high cholesterol diet. After balloon injury, rabbits were randomly divided into three groups: the untreated group (n¼31) received no treatment, the scrambled group (n¼31) underwent transfection of the scrambled decoy ODN at the balloon injury site, 
n¼33) underwent transfection of the Egr-1 decoy at the balloon injury site. Before insertion of the catheter, heparin (100 IU) was intravenously injected. For transfection of the decoy ODN, the pulse infusion catheter (Aishin Human Systems Co, Japan) was introduced into the injured common carotid artery site via the right external carotid artery immediately after balloon injury. A measure of 1 ml of the ODN solution (1 mg/1 ml, 80 mM) was infused via the catheter under a 300 mmHg pressure for 15 min. The infusion catheter was then removed and blood flow of the common carotid artery was re-established. At various time points after the operation, rabbits of each group were anesthetized and the injured or transfected common carotid arteries as well as the contralateral untransfected, unmanipulated carotid arteries were collected.
To determine the time course of Egr-1 protein expression, immunohistochemical staining for Egr-1 was performed in a rat model of carotid artery balloon injury. A rat model was used because the appropriate (rabbit Egr-1) antibody was not available. Male WistarKyoto rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and balloon injury of the right common carotid artery was performed using an inflated 2F Fogarty balloon catheter. 23 
Analysis of FITC-ODNs
FITC-labeled ODN were instilled into the injured carotid arteries as above and the arteries were harvested 24 h after transfection. The efficacy of FITC-labeled ODN was assessed using a fluorescence microscope. Serial 5 mm cryosections of carotid arteries transfected with Egr-1 with FITC-labeled ODNs were prepared and recorded. Transfected cells were identified by enhancement of the fluorescein signal.
Electrophoretic mobility shift assay (EMSA)
The EMSA was performed on nuclear extracts prepared immediately from rabbit carotid arteries 2 h after injury using the method described previously. 17, 27 Two carotid arteries were pooled so as to obtain one sample for one EMSA. Double-stranded ODN probes for Egr-1 (Santa 
Histopathology and immunohistochemistry
The rabbit common carotid arteries were harvested, fixed with 10% paraformaldehyde or methacarn solution (methanol 60%; 1,1,1-trichloroethane 30%; and glacial acetic acid 10%). Sections were either stained with elastic-van Gieson stain or subjected to immunostaining. For immunohistochemistry, the slides were heated to induce epitope retrieval. To reduce nonspecific reactivity, sections were preincubated with 0.3% hydrogen peroxide and normal bovine serum. The primary antibodies used in the present study were as follows: mouse anti-rabbit macrophage antibody RAM11 (DAKO Co), the mouse anti-human The rat common carotid arteries were harvested, fixed with methacarn solution, embedded in paraffin, and cut into 5-mm thick sections. Sections were first stained with primary antibodies, rabbit anti-rat Egr-1 IgG (Santa Cruz Biotechnology), sequentially treated with a biotinylated species-specific secondary antibody, and stained with streptavidin-conjugated peroxidase substrate (Nichirei, Tokyo, Japan). The slides were counterstained with hematoxylin. Immunofluorescence double staining was performed to localize Egr-1 by the use of fluorescenceconjugated antibodies. The primary antibodies used in this study were mouse anti-rat ED-1 (Serotec), mouse a-smooth muscle actin (Dako), goat anti-PECAM (Santa Cruz).
Morphometric analysis
Morphometry and cell counting were performed by a single observer who was blind to the treatment protocols. To evaluate the neointimal thickening of the rabbit carotid arteries, the neointima to media ratio (I/M ratio) was measured using a computer-assisted analyzer (NIH Image).
Each tissue (four sections per artery) stained with RAM11 and Ki-67 was scanned. The number of positive cells in each section was determined. The sum of the immunopositive cells and the number of total cells in each section were counted. Then the percentage of immunopositive cells per total cells in each section was calculated, and the average of the four sections was reported for each animal. Real-time polymerase chain reaction (PCR) amplification was performed with the rabbits' cDNA using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) as described previously. 23 The respective PCR primers and TaqMan probes were designed from GenBank databases using a software program (Applied Biosystems; Table 1 ). The results were analyzed using the Sequence Detection Software (Applied Biosystems) and expressed in arbitrary units and adjusted for GAPDH mRNA levels.
Statistical analysis
Data are expressed as the mean7s.e. Statistical analysis of differences was compared by the analysis of variance and Bonferroni's multiple comparison tests. A P-value of less than 0.05 was considered to be statistically significant.
